Last deal

$22M

Amount

Series C

Stage

18.12.2019

Date

1

all rounds

$22M

Total amount

date founded

Financing round

General

About Company
Raziel Health is a company that delivers fully integrated healthcare services to people in the comfort and safety of their own homes.

Industry

Sector :

Subsector :

Also Known As

Raziel Therapeutics

founded date

01.01.2012

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

By leveraging user-friendly technologies and data analytics, Raziel Health aims to make high-quality healthcare more accessible and affordable. Their innovative approach combines easy-to-use tools for patients, timely clinical intervention, and personalized goal-setting. Additionally, the company has developed injectable drugs that effectively reduce submental fat and fat disorders like Dercum's disease. Through a single injection treatment, healthcare professionals can achieve long-lasting fat reduction without invasive procedures, providing patients with significant results.
Similar Companies
994
Exvastat

Exvastat

Exvastat is a preclinical-stage pharmaceutical company that develops drugs to cure acute respiratory distress syndrome.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, UK

total rounds

2

total raised

$3.9M
Galleon Pharmaceuticals

Galleon Pharmaceuticals

Galleon Pharmaceuticals develops medicines for breathing-control conditions in the US.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Health Care, Pharmaceuticals, Medical

Location

Horsham, PA, USA

total rounds

8

total raised

$53M
Nexalin Technology

Nexalin Technology

Nexalin Technology develops transcranial electrical stimulation equipment for the treatment of anxiety, insomnia, and depression.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Medical Device

Location

Houston, TX, USA

total rounds

2

total raised

$5.75M
SEEK Group

SEEK Group

SEEK Group develops pharmaceutical drugs to improve human health by bringing safe, effective and low-cost treatments to patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

London, UK

Financials

Funding Rounds
1
1

Number of Funding Rounds

$22M

Money Raised

Their latest funding was raised on 18.12.2019. Their latest investor Shmuel Cabilly. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
18.12.2019
6
$22M
Pontifax

Pontifax

Pontifax is a healthcare-dedicated venture capital firm that finances pharmaceutical and life sciences companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Herzliya, Israel

count Of Investments

97

count Of Exists

9
Co-Investors
Investors
6
1

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series C
Yes
Series C
No
Series C
Shmuel Cabilly

Shmuel Cabilly

Dr. Cabilly is a highly regarded scientist, an investor and an experienced Board Member of several companies. He is currently a Board Member of Medasense Biometrics Ltd. He previously worked for several companies including as the Co-Founder and a Chief Scientist of Ethrog Biotechnology which was sold to Invitrogen. Dr. Cabilly graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. This invention was patented in world patents “The old Cabilly” and “The New Cabilly patent”. Today there are already 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more.

current job

Ethrog Biotech

count Of Investments

3

count Of Exists

1
Pontifax

Pontifax

Pontifax is a healthcare-dedicated venture capital firm that finances pharmaceutical and life sciences companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Herzliya, Israel

count Of Investments

97

count Of Exists

9

Wille AG

Wille AG

Location

Zürich, Switzerland

count Of Investments

7

count Of Exists

1
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Ideal Life acquired by Raziel Health

Ideal Life acquired by Raziel Health

acquirer

Raziel Health
Raziel Health

date

03.04.2020

type

Acquisition
Ideal Life

Ideal Life

Ideal Life is a leading technology company in the connected health industry.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care, Information Technology

Location

Toronto, ON, Canada

People

Founders
1
Jeffery Gruen
Jeffery Gruen

Jeffery Gruen

Jeff Gruen is Huron’s Chief Clinical Innovation Officer and a member of the firm’s Healthcare leadership team. He has a distinguished career as an executive, entrepreneur and advisor working across industries with a focus on population health, ACO risk models and care management. Dr. Gruen has been a leader in four digital health/care delivery model innovation companies, including Revolution Health Group, where he served as President of the Care Division. He also has extensive experience in managing risk at the interface between payers and providers and served as a Chief Medical Officer at United Health Group.

current job

Raziel Health
Raziel Health

organization founded

1

Jeffery Gruen

Employee Profiles
1
Jeffery Gruen

Jeffery Gruen

Founder & CEO

Activity

Recent News
0